ReviewCurrent oncology reports2018
Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer.
Review in Current oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Stereotactic versus whole-brain radiotherapy combined with immunotherapy in driver gene-negative NSCLC with brain metastases: a real-world IPTW analysis.Frontiers in immunology · 2026Article
- Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.JAMA network open · 2025Observational
- Prognostic factors, patterns of failure and re-irradiation in hypofractionated stereotactic radiotherapy-treated brain metastases from non-small cell lung cancer.Clinical and translational radiation oncology · 2025Article
- Recapitulated Crosstalk between Cerebral Metastatic Lung Cancer Cells and Brain Perivascular Tumor Microenvironment in a Microfluidic Co-Culture Chip.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine.Frontiers in oncology · 2022Article
- Analysis of Immunotherapy Combined with Radiotherapy in Patients with Brain Metastasis of Driver Gene-Negative Non-Small-Cell Lung Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Risk factor of brain metastases and its influence on patient prognosis after complete resection of non-small cell lung cancer.American journal of translational research · 2022Article
- Oligometastatic non-small cell lung cancer: Current management.Journal of clinical and translational research · 2021Review
- WBRT for brain metastases from non-small cell lung cancer: for whom and when?-Contemporary point of view.Journal of thoracic disease · 2021Review
- Local ablative therapy of brain metastasis from non-small cell lung cancer: benefits and limitations.Journal of thoracic disease · 2021Review
- Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Review
- Public interest in stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) in the United States.Journal of radiosurgery and SBRT · 2020Article
- Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions.World journal of clinical oncology · 2019Review
- Direct comparison between surface imaging and orthogonal radiographic imaging for SRS localization in phantom.Journal of applied clinical medical physics · 2019Article
- Prognostic value of site-specific metastases in lung cancer: A population based study.Journal of Cancer · 2019Article
- ALK expression favorably impacts the prognosis ofOncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo summarize current approaches in the management of brain metastases from non-small cell lung cancer (NSCLC). RECENT
findingsLocal treatment has evolved from whole-brain radiotherapy (WBRT) to increasing use of stereotactic radiosurgery (SRS) alone for patients with limited (1-4) brain metastases. Trials have established post-operative SRS as an alternative to adjuvant WBRT following resection of brain metastases. Second-generation TKIs for ALK rearranged NSCLC have demonstrated improved CNS penetration and activity. Current brain metastasis trials are focused on reducing cognitive toxicity: hippocampal sparing WBRT, SRS for 5-15 metastases, pre-operative SRS, and use of systemic targeted agents or immunotherapy. The role for radiotherapy in the management of brain metastases is becoming better defined with local treatment shifting from WBRT to SRS alone for limited brain metastases and post-operative SRS for resected metastases. Further trials are warranted to define the optimal integration of newer systemic agents with local therapies.
Indexed as
Identifiers
29736685What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.